SpringLeaf Therapeutics Closes on $4M
SpringLeaf Therapeutics held a second closing of its Series B round, inking an additional $4 million from new investor Excel Venture Management. The total for the round now stands at $19 million. The company’s other investors include SR One, Flybridge Capital Partners, and North Bridge Venture Partners. SpringLeaf is based in Boston.
8 July 2011•3 mins read
